Ielasi Alfonso, Tespili Maurizio
Division of Cardiology, 'Bolognini' Hospital, Via Paderno 21, 24068, Seriate (BG), Italy.
Future Cardiol. 2014 May;10(3):409-20. doi: 10.2217/fca.14.14.
Despite improvements in stent platform, polymer and drug elution, the permanent metallic stents have significant limitations as they distort vessel physiology, predispose to late thrombosis and may preclude surgical revascularization. Bioresorbable scaffold (BRS) technology has evolved over the last few years to overcome these drawbacks. Actually, different BRS are either available or under clinical and preclinical investigation. However, the use of BRS has largely been restricted to patients recruited into clinical trials with a relatively small number of 'real world' patients treated with these devices. Here, we highlight the potentialities of these devices, describe the evidence from the recent clinical trials and discuss the potential advantages, as well as challenges, that this novel technology may face in routine clinical practice.
尽管在支架平台、聚合物和药物洗脱方面有所改进，但永久性金属支架仍有显著局限性，因为它们会扭曲血管生理，易引发晚期血栓形成，并且可能妨碍外科血管重建。在过去几年中，生物可吸收支架（BRS）技术不断发展以克服这些缺点。实际上，不同的BRS已经上市或正在进行临床和临床前研究。然而，BRS的使用在很大程度上仅限于招募到临床试验中的患者，接受这些装置治疗的“真实世界”患者数量相对较少。在此，我们强调这些装置的潜力，描述近期临床试验的证据，并讨论这项新技术在常规临床实践中可能面临的潜在优势以及挑战。
